{"id":"W2088614543","doi":"10.1007/s11894-012-0311-3","title":"Novel Targets for Inflammatory Bowel Disease Therapeutics","year":2013,"lang":"en","type":"review","venue":"Current Gastroenterology Reports","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":31,"is_retracted":false,"has_abstract":false,"ca_institutions":"Robarts Clinical Trials","funders":"","keywords":"Ustekinumab; Tofacitinib; Vedolizumab; Medicine; Inflammatory bowel disease; Monoclonal antibody; Ulcerative colitis; Immunology; Crohn's disease; Clinical trial; Monoclonal; Janus kinase; Disease; Infliximab; Antibody; Internal medicine; Cytokine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002739374,0.0008802629,0.001032169,0.0002205939,0.0001623062,0.0000817632,0.0004509309,0.0004608692,0.00003826997],"category_scores_gemma":[0.0001264324,0.0008261378,0.001272885,0.00004266928,0.0002951524,0.00001062597,0.0003583205,0.0003729725,0.00003944394],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008545432,"about_ca_system_score_gemma":0.0007185896,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000001022645,"about_ca_topic_score_gemma":0.00001149167,"domain_scores_codex":[0.9960548,0.0001691648,0.001355745,0.001279097,0.0002273243,0.0009139079],"domain_scores_gemma":[0.9964575,0.00002015258,0.00129477,0.001464112,0.0002511572,0.0005122868],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001695538,0.002808404,0.03451203,0.07753927,0.005141726,0.002500503,0.00005852101,0.00005718551,0.0005009843,0.0001312235,0.09246699,0.7825876],"study_design_scores_gemma":[0.0004499651,0.0001276764,0.001559799,0.0009704164,0.001272484,0.0003146874,0.000001941159,0.000009969761,0.000002859138,0.00002596162,0.9947937,0.0004706137],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001850852,0.9886504,0.002541386,0.00002022141,0.003079972,0.003389935,0.0003861379,0.00006229155,0.00001879101],"genre_scores_gemma":[0.0001100312,0.9899573,0.0003345184,0.0001776935,0.001362069,0.003228166,0.004313599,0.0002115094,0.0003050897],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9023266,"threshold_uncertainty_score":0.999419,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03379967257626593,"score_gpt":0.3142006582837941,"score_spread":0.2804009857075281,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}